India's first mRNA-based Omicron-specific COVID-19 booster shot from Gennova Biopharmaceuticals, a needle-free vaccine, is under scrutiny by the subject experts' committee (SEC) under the drug regulatory authority
A spike in the number of COVID-19 cases prompted the Pune-based Gennova Biopharmaceuticals to submit data to the drug regulator.
The company conducted Phase II/III trials and submitted the results to the Drugs Controller General of India (DCGI). The trial was conducted on 3,200 participants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze